Artiva Biotherapeutics, Inc (ARTV)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Artiva Biotherapeutics, Inc (ARTV) is up 62.5% since the beginning of the year. At $7 per share, ARTV is trading 52.0% below its 52-week high of $15.

Artiva Biotherapeutics, Inc (ARTV) has returned 62.47% so far this year and 257.44% over the past 12 months.

Based on dividend-adjusted daily data since Jul 19, 2024, ARTV's average daily return is +0.30%, while the average monthly return is +2.63%. At this rate, an investment would double in approximately 2.2 years.

Historically, 38% of months were positive and 63% were negative. The best month was Jul 2025 with a return of +98.7%, while the worst month was Jan 2025 at -49.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ARTV closed higher 46% of trading days. The best single day was Oct 17, 2025 with a return of +117.0%, while the worst single day was Apr 8, 2025 at -42.0%.

Artiva Biotherapeutics, Inc has an annualized alpha of 58.94%, beta of 1.55, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since July 22, 2024.

• This stock participated in 326.12% of S&P 500 Index downside but only 68.70% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ARTV ranks 88 for risk / return — in the top 88% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Artiva Biotherapeutics, Inc (ARTV) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Artiva Biotherapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Artiva Biotherapeutics, Inc was 90.71%, occurring on Jun 27, 2025. The portfolio has not yet recovered.

The current Artiva Biotherapeutics, Inc drawdown is 55.97%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Artiva Biotherapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Artiva Biotherapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.